Objective(s) Roux-en-Y Gastric Bypass (RYGB) is well known to ameliorate type 2 diabetes mellitus (T2DM), and recent work suggests that the preoperative DiaREM model predicts successful remission up to 1 year post-RYGB. However, no data exist for long-term validity. Therefore, we sought to determine the utility of this score on longterm RYGB effectiveness for T2DM resolution at 2 and 10 years, respectively. Methods T2DM patients (Age: 48, BMI: 49, HbA 1C : 8.1) undergoing RYGB at the University of Virginia between 2004-2006 (n = 42) and 2012-2014 (n = 59) were evaluated prospectively to assess preoperative DiaREM score, defined from insulin use, age, HbA 1C , and type of antidiabetic medication. T2DM partial remission status was based on the American Diabetes Association guidelines (HbA 1C \ 6.5 % and fasting glycemia \125 mg/dL, and no anti-diabetic medications). Chi-square test was used to compare patient's T2DM status to their DiaREM probability of remission.
(RYGB) for comorbidity reduction including dyslipidemia, hypertension, and type 2 diabetes mellitus (T2DM) [5] [6] [7] [8] . In fact, a large retrospective analysis reported that 83 % of patients undergoing RYGB had improvement or remission of T2DM at 1-year follow-up [9] . Given the high complication rates of blindness, amputation, cardiovascular, and end-stage renal disease in poorly controlled diabetics, there has been wide acceptance of RYGB for the management/ treatment for metabolic disease in severely obese patients [10] . However, recent work suggests that preoperative clinical (e.g., age, BMI) and biological markers (e.g., inflammation, glucose) predict responsiveness to RYGB for weight loss and diabetes remission [11] [12] [13] [14] . This suggests that not all people derive equal benefit from bariatric surgery, and better assessment tools are needed prior to surgery to understand who is likely to meet T2DM remission criteria and obtain the best results.
A number of T2DM remission predictors have been developed over the past 10 years to better risk stratify obese patients with T2DM for bariatric surgery [15] [16] [17] [18] . The Dia-REM score developed by Still et al. has been validated with several papers reporting short-and midterm accuracy and accepted by clinicians as a reasonable prediction tool for the remission of T2DM [19, 20] . However, this tool has not been studied beyond 2 years postoperatively, thereby limiting the long-term understanding of how reliable this tool is for overall glucose management. Recently, our group demonstrated the long-term durability of T2DM resolution following RYGB at 10 years [21] . However, it is unknown whether preoperative DiaREM score would predict long-term T2DM remission following RYGB. Therefore, the purpose of this study was to assess whether the DiaREM score was a valid predictor of the long-term accuracy of this T2DM remission. We hypothesized that the DiaREM score would successfully predict shortterm (2-year) and long-term (10-year) T2DM remissions. [ 6.5 % [22] . A DiaREM score for each patient was calculated based on their preoperative age, HbA 1c , and diabetic medications using the method described by Still et al. [10, 19] . Analogous to this prior work [10, 19] , we combined ''partial remission'' and ''complete remission'' for final analysis. Specifically, ''partial'' remission of T2DM was defined by HbA 1c \ 6.5 %, fasting blood glucose levels \125 mg/dL, and no use of anti-diabetic medications for a minimum of 12 months. ''Complete'' remission was defined by HbA 1c \ 6.0 %, fasting glucose \100 mg/dL, and no use of anti-diabetic medication for least 12 months [22] .
Patients and methods

Patients
Statistical analysis
The primary outcome for this study was actual T2DM remission at 2 and 10 years compared with expected remission based on DiaREM score. Secondary outcomes include diabetes-specific outcomes for patients 2 and 10 years after RYGB. Data were compared using Chisquare test (v 2 test), and a p \ 0.05 was used for statistical significance. SAS version 9.4 (SAS Company, Cary NC) was used for statistical analyses.
Results
Preoperative T2DM incidence
There were 120 patients who underwent RYGB in the 2-year follow-up group and 489 patients in the 10-year follow-up group. Within this population, 59 and 42 people with T2DM met criteria for DiaREM modeling in the 2-and 10-year groups, respectively. Among RYGB patients with 2-year postoperative data, 2 were lost (n = 1 no follow-up and n = 1 died) resulting in 57 (98 % follow-up) patients for analysis. For the 10-year postoperative data, 11
were lost (n = 6 no follow-up and n = 5 died), thereby resulting in only 31 (74 % follow-up) patients for analysis ( 
2-and 10-Year T2DM remission
In the 2-year group, 65 % of people achieved T2DM remission while the 10-year group had 58 % with T2DM remission. Using the methods of Still et al. [10, 19] , we stratified the DiaREM scores into five groups with corresponding remission rates: 0-2 (88-99 %), 3-7 (64-88 %), 8-12 (23-49 %), 13-17 (11-33 %), 18-22 (2-16 %). Each group was listed with the correlating percent remission from the original study. The results in Table 2 display the percent of patients across the preoperative risk criteria for the cohorts at 2 and 10 years, and highlights that the majority of patients fell within the 3-7 and 8-12 score range. Finally, Table 3 shows the percent remission of T2DM for our two cohorts compared to that reported by Still and colleagues [10, 19] . There was no difference in percent remission of T2DM in the 2-or 10-year groups compared to the prediction based on DiaREM score (all p [ 0.05; Table 3 ; Fig. 1 ).
Discussion
The novel finding from this study is that the DiaREM score provides long-term (10-year) validation predicting T2DM remission following RYGB. This finding is consistent with prior studies reporting short-term validation of DiaREM [20] . Despite our current understanding of the reasons for RYGB effectiveness on T2DM, reports suggest that nearly half of people may not maintain T2DM remission overtime. As a result, we recognize that RYGB serves to reset the system, but it is critical for patients to fundamentally change their lifestyles. In either case, our data suggest that using the DiaREM score to predict improved glycemic control in patients following RYGB is a reasonable way to identify people likely to respond to RYGB for diabetes management [9] . As shown in Table 3 , the percent of patients across the preoperative risk criteria highlights that the majority of patients fell within the 3-7 and 8-12 score range, suggesting moderate risk for not meeting T2DM remission as reported for the Still et al. cohort. Ultimately, this prediction tool will allow better risk stratification and patient selection for RYGB as validated by both our center at 2 and 10 years as well as the Cleveland Clinic group at 2-4 years [20] . The standard population undergoing this population has changed over the past 10-15 years as evidenced by the growing majority of patients undergoing Illustrates the percentage of patients within each DiaREM score range between the 2-year and 10-year groups. High score reflects elevated risk and low propensity for diabetes remission. As demonstrated, a majority of patients in both groups had intermediate scores [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] RYGB at our institution being females while we are operating on older patients with higher HbA 1C (Table 1) . In our population, diabetes remission was typically higher than predicted, although there was no statistical difference in the proportions predicted versus actual. To be congruent with the original model by Still et al. [19] , we used a combination of ''partial remission'' and ''complete remission'' to validate the long-term durability of RYGB on T2DM remission. While this method captures more patients in the remission group compared with using only ''complete remission,'' it accurately reflects the improvement in glucose control and provides value to the outcome of the operation. As pointed out by several groups, the partial remission group is likely to proceed to complete remission, resulting in the phenomenon of late remission [19, 20, 23] . The difference in timing of diabetes remission likely represents gastrointestinal signaling pathways versus weight loss-induced remission of T2DM [9, 24] . Indeed, since Pories et al. [25] first described the rapid amelioration of T2DM after RYGB, a vast amount of research has gone into elucidating the pathophysiology and identifying potential drug targets. We did not assess the mechanism by which RYGB contributed to long-term T2DM remission as this is beyond the scope of the current study. However, changes in insulin sensitivity and beta-cell function are likely key determinants. In either case, our results suggest that diabetes remission up to 10 years is highly probable, and preoperative factors including HbA 1c , age, insulin usage, and antidiabetic oral medications provide a good tool for predicting the resolution of diabetes.
There are limitations of this study that may affect our interpretations. Our sample size is modest, and we have incomplete clinical outcomes to understand the mechanism by which RYGB induces and maintains T2DM remission. Next, this study design includes retrospective analysis without the same cohort of people measured serially overtime, thereby limiting our ability to make causal inference on the ability of RYGB to have durable effects on glucose control. However, our database has been prospectively collected for the past 30 years and is regularly updated when patients are seen at follow-up. There have been efforts to maintain yearly follow-up beyond 2 years, but due to the large referral base, the geographic distance of many patients from our medical center, the role of primary care physicians in following these patients on a regular basis, and the cost and time of visits for the patient who feel well and in good health, achieving complete follow-up in person have been challenging. Nevertheless, this study represents the first evaluation of the DiaREM model in T2DM patients up to 10 years after bariatric surgery, and our results suggest it is a valid approach for predicting those likely to meet diabetes remission, Lastly, telephone follow-up was used to characterize diabetes remission and some clinical-related outcomes for the Dia-REM score. While telephone screening likely improved the yield at 10-year follow-up, it is limited by the lack of objectivity and subject bias for willingness to answer questions. However, telephone follow-up has been validated in the bariatric population by Harper et al. [26] , and our approach provides novel insight to the capability of the DiaREM score on understanding the durability of RYGBinduced diabetes remission. Demonstrates DiaREM probability of diabetes remission versus actual remission for each score at both 2 and 10 years 
Conclusion
In conclusion, the major finding in the present study reports that the preoperative DiaREM scores are a good tool for predicting both short-and long-term T2DM remissions following RYGB. The current report of 10-year results suggests that many people meet diabetes remission. However, these data point toward a critical shift in focus toward long-term care of patients after RYGB. Subsequently, the DiaREM score appears to be a valid long-term predictor of T2DM remission after RYGB, and represents a potential strategy to identify individuals who are likely to reach T2DM remission. Further work is required to determine optimal medical strategies based on preoperative health for optimizing RYGB-induced diabetes remission in those people at highest risk.
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